A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

**Study Purpose:** The primary objective of the study is to assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile.

**Recruitment Information:**

**Study Type:** This interventional study is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the safety and efficacy of Ravulizumab in complement-inhibitor-naïve adult patients with generalized Myasthenia Gravis.

**Status:** Recruiting

**Target Patient:** A male or female (aged 18 years or older) with a diagnosis of generalized Myasthenia Gravis (MG) meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) Class II to IV.

**Eligible Ages:** ≥ 18 years

To assist in determining your eligibility, please fill out this eligibility survey.

**See the study details online:**

**Inclusion and Exclusion Criteria:**

**Inclusion Criteria:** Patients diagnosed with Myasthenia Gravis at least 6 months prior to the date of the Screening Visit as confirmed by specific criteria. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening. Patients must be vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis). Other, more specific inclusion criteria are further defined in the protocol.

**Exclusion Criteria:** Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening. History of thymectomy within the 12 months prior to screening. History of N meningitidis infection. Participants who have received previous treatment with complement inhibitors (for example, eculizumab). Other, more specific exclusion criteria are further defined in the protocol.
Study Information:

Sponsor: Alexion Pharmaceuticals, Inc.
Principal Investigator:
Study Coordinator:
Type of Study: Interventional
Study Duration: 132 weeks
Single Center/Multi-center: Multi-center
Travel Funds Available: ☑ Y ☐ N

For more information, please view this downloadable brochure or send questions to mgchampion@alexion.com.

Find A Center Near You

Site:
PI:
Coordinator: